Vemurafenib in patients With RAI refractory, progressive, BRAFV600E-mutated papillary thyroid cancer

Vemurafenib may offer sorely needed novel treatment for a subset of patients with metastatic or unresectable papillary thyroid cancer that is resistant to radioactive iodine therapy. Vemurafenib demonstrated antitumour activity in the phase II study of patients with BRAFV600E-mutated papillary thyroid cancer who were either tyrosine kinase inhibitor (TKI) treatment naive or had received prior TKI treatments; however treatment naive patients showed greater benefit. Read more here.